XBiotech
XBIT
25 hedge funds and large institutions have $5.68M invested in XBiotech in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
17% more capital invested
Capital invested by funds: $4.85M → $5.68M (+$832K)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 24 → 25 (+1)
1.14% less ownership
Funds ownership: 4.26% → 3.12% (-1.1%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
81% less call options, than puts
Call options by funds: $61K | Put options by funds: $321K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$515K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$86.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71.8K |
| 4 |
VF
Virtu Financial
New York
|
+$64.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.63M |
| 2 |
Millennium Management
New York
|
-$465K |
| 3 |
ECM
Element Capital Management
New York
|
-$96K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$85K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$56.2K |
XBIT Hedge Fund Activity: Q4 2018 in Review
25 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2018, worth a combined $5.68M — up 17% from $4.85M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new XBIT positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $515K. The largest seller was Vanguard Group, cutting an estimated $1.63M.
- 25 institutional investors held XBiotech (XBIT) as of Q4 2018, up from 24 in Q3 2018.
- Funds reported $5.68M of XBiotech stock for Q4 2018, up 17% quarter-over-quarter.
- 7 funds opened new XBiotech positions in Q4 2018 and 6 closed out, a net change of +1 holder.
- The largest XBiotech buyer in Q4 2018 was EAM Investors, an estimated $515K added.
- The largest XBiotech seller in Q4 2018 was Vanguard Group, an estimated $1.63M sold.
Based on aggregated 13F filings for Q4 2018.